Literature DB >> 16044808

A study on trend of relapse in leprosy and factors influencing relapse.

M K Showkath Ali1, D M Thorat, M Subramanian, G Parthasarathy, U Selvaraj, V Prabhakar.   

Abstract

A retrospective analysis of data pertaining to the rural field operation area of the Central Leprosy Teaching and Research Institute, Chengalpattu, Tamil Nadu, was carried out to determine the magnitude of relapse after MDT and its significance with other variables. The study included 3248 leprosy patients who have successfully completed treatment during 1987-2003, of whom 2892 were PB and 356 MB cases. A total of 58 cases of relapse was reported which gives a crude cumulative relapse rate of 1.78% for the 16-year period of follow-up and the rates for PB and MB were 1.9% and 0.84% respectively. With respect to PB cases, 68% of relapses were reported in the first 3 years of RFT. The person-year relapse rate was highly significant with regard to the number of skin lesions (p<0.0002) and nerve involvement (p<0.0002). The person-year relapse rate did not differ significantly between PB and MB leprosy, male and female, and child and adult cases. RFT year cohort relapse rate reveals that the introduction of MB-MDT regimen for PB leprosy had resulted in the reduction of relapses among PB cases after 1998. The relapse rate with reference to the time gap after RFT reveals that relapse declines with passage of time after RFT. The risk of relapse was very low in both PB and MB leprosy which fact emphasizes that proper counselling about signs and symptoms of relapse during RFT is adequate to combat the problem. A majority of relapses occurred in the first three years after RFT. The number of skin lesions and involvement of nerves were the main risk factors for relapse.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044808

Source DB:  PubMed          Journal:  Indian J Lepr        ISSN: 0254-9395


  4 in total

1.  Six months fixed duration multidrug therapy in paucibacillary leprosy: risk of relapse and disability in Agra PB cohort study.

Authors:  Anil Kumar; Anita Girdhar; Bhavneswar Kumar Girdhar
Journal:  BMJ Open       Date:  2012-08-13       Impact factor: 2.692

2.  Correlation between Central Memory T Cell Expression and Proinflammatory Cytokine Production with Clinical Presentation of Multibacillary Leprosy Relapse.

Authors:  Danuza Esquenazi; Iris Maria Peixoto Alvim; Roberta Olmo Pinheiro; Eliane Barbosa de Oliveira; Lilian de Oliveira Moreira; Euzenir Nunes Sarno; Jose Augusto da Costa Nery
Journal:  PLoS One       Date:  2015-05-19       Impact factor: 3.240

3.  Low risk of relapse and deformity among leprosy patients who completed multi-drug therapy regimen from 2005 to 2010: A cohort study from four districts in South India.

Authors:  Prabu Rajkumar; Girish Kumar Chethrapilly Purushothaman; Manickam Ponnaiah; Devika Shanmugasundaram; Jayasree Padma; Rang Lal Meena; Selvaraj Vadivoo; Sanjay M Mehendale
Journal:  PLoS Negl Trop Dis       Date:  2021-11-23

4.  Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study.

Authors:  Anil Kumar; Anita Girdhar; B K Girdhar
Journal:  Indian J Med Res       Date:  2013-10       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.